Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Lignende værker

• Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
  af: James F. Donohue, et al.
  Udgivet: (2020-05-01)
• Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
  af: Donohue, James F., et al.
  Udgivet: (2019)
• Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials
  af: Ferguson, Gary T., et al.
  Udgivet: (2019)
• Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate
  af: Mahler, Donald A., et al.
  Udgivet: (2019)
• Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
  af: Donohue, James, et al.
  Udgivet: (2019)